Cargando…

Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate

BACKGROUND: Hybrid magnetic resonance (MR)-Linac systems have recently been introduced into clinical practice. The systems allow online adaption of the treatment plan with the aim of compensating for interfractional anatomical changes. The aim of this study was to evaluate the dose volume histogram...

Descripción completa

Detalles Bibliográficos
Autores principales: Nierer, Lukas, Eze, Chukwuka, da Silva Mendes, Vanessa, Braun, Juliane, Thum, Patrick, von Bestenbostel, Rieke, Kurz, Christopher, Landry, Guillaume, Reiner, Michael, Niyazi, Maximilian, Belka, Claus, Corradini, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917666/
https://www.ncbi.nlm.nih.gov/pubmed/35279185
http://dx.doi.org/10.1186/s13014-022-02021-6
_version_ 1784668597928329216
author Nierer, Lukas
Eze, Chukwuka
da Silva Mendes, Vanessa
Braun, Juliane
Thum, Patrick
von Bestenbostel, Rieke
Kurz, Christopher
Landry, Guillaume
Reiner, Michael
Niyazi, Maximilian
Belka, Claus
Corradini, Stefanie
author_facet Nierer, Lukas
Eze, Chukwuka
da Silva Mendes, Vanessa
Braun, Juliane
Thum, Patrick
von Bestenbostel, Rieke
Kurz, Christopher
Landry, Guillaume
Reiner, Michael
Niyazi, Maximilian
Belka, Claus
Corradini, Stefanie
author_sort Nierer, Lukas
collection PubMed
description BACKGROUND: Hybrid magnetic resonance (MR)-Linac systems have recently been introduced into clinical practice. The systems allow online adaption of the treatment plan with the aim of compensating for interfractional anatomical changes. The aim of this study was to evaluate the dose volume histogram (DVH)-based dosimetric benefits of online adaptive MR-guided radiotherapy (oMRgRT) across different tumor entities and to investigate which subgroup of plans improved the most from adaption. METHODS: Fifty patients treated with oMRgRT for five different tumor entities (liver, lung, multiple abdominal lymph nodes, pancreas, and prostate) were included in this retrospective analysis. Various target volume (gross tumor volume GTV, clinical target volume CTV, and planning target volume PTV) and organs at risk (OAR) related DVH parameters were compared between the dose distributions before and after plan adaption. RESULTS: All subgroups clearly benefited from online plan adaption in terms of improved PTV coverage. For the liver, lung and abdominal lymph nodes cases, a consistent improvement in GTV coverage was found, while many fractions of the prostate subgroup showed acceptable CTV coverage even before plan adaption. The largest median improvements in GTV near-minimum dose (D(98%)) were found for the liver (6.3%, p < 0.001), lung (3.9%, p < 0.001), and abdominal lymph nodes (6.8%, p < 0.001) subgroups. Regarding OAR sparing, the largest median OAR dose reduction during plan adaption was found for the pancreas subgroup (-87.0%). However, in the pancreas subgroup an optimal GTV coverage was not always achieved because sparing of OARs was prioritized. CONCLUSION: With online plan adaptation, it was possible to achieve significant improvements in target volume coverage and OAR sparing for various tumor entities and account for interfractional anatomical changes.
format Online
Article
Text
id pubmed-8917666
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89176662022-03-21 Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate Nierer, Lukas Eze, Chukwuka da Silva Mendes, Vanessa Braun, Juliane Thum, Patrick von Bestenbostel, Rieke Kurz, Christopher Landry, Guillaume Reiner, Michael Niyazi, Maximilian Belka, Claus Corradini, Stefanie Radiat Oncol Research BACKGROUND: Hybrid magnetic resonance (MR)-Linac systems have recently been introduced into clinical practice. The systems allow online adaption of the treatment plan with the aim of compensating for interfractional anatomical changes. The aim of this study was to evaluate the dose volume histogram (DVH)-based dosimetric benefits of online adaptive MR-guided radiotherapy (oMRgRT) across different tumor entities and to investigate which subgroup of plans improved the most from adaption. METHODS: Fifty patients treated with oMRgRT for five different tumor entities (liver, lung, multiple abdominal lymph nodes, pancreas, and prostate) were included in this retrospective analysis. Various target volume (gross tumor volume GTV, clinical target volume CTV, and planning target volume PTV) and organs at risk (OAR) related DVH parameters were compared between the dose distributions before and after plan adaption. RESULTS: All subgroups clearly benefited from online plan adaption in terms of improved PTV coverage. For the liver, lung and abdominal lymph nodes cases, a consistent improvement in GTV coverage was found, while many fractions of the prostate subgroup showed acceptable CTV coverage even before plan adaption. The largest median improvements in GTV near-minimum dose (D(98%)) were found for the liver (6.3%, p < 0.001), lung (3.9%, p < 0.001), and abdominal lymph nodes (6.8%, p < 0.001) subgroups. Regarding OAR sparing, the largest median OAR dose reduction during plan adaption was found for the pancreas subgroup (-87.0%). However, in the pancreas subgroup an optimal GTV coverage was not always achieved because sparing of OARs was prioritized. CONCLUSION: With online plan adaptation, it was possible to achieve significant improvements in target volume coverage and OAR sparing for various tumor entities and account for interfractional anatomical changes. BioMed Central 2022-03-12 /pmc/articles/PMC8917666/ /pubmed/35279185 http://dx.doi.org/10.1186/s13014-022-02021-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nierer, Lukas
Eze, Chukwuka
da Silva Mendes, Vanessa
Braun, Juliane
Thum, Patrick
von Bestenbostel, Rieke
Kurz, Christopher
Landry, Guillaume
Reiner, Michael
Niyazi, Maximilian
Belka, Claus
Corradini, Stefanie
Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
title Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
title_full Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
title_fullStr Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
title_full_unstemmed Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
title_short Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
title_sort dosimetric benefit of mr-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917666/
https://www.ncbi.nlm.nih.gov/pubmed/35279185
http://dx.doi.org/10.1186/s13014-022-02021-6
work_keys_str_mv AT niererlukas dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT ezechukwuka dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT dasilvamendesvanessa dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT braunjuliane dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT thumpatrick dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT vonbestenbostelrieke dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT kurzchristopher dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT landryguillaume dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT reinermichael dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT niyazimaximilian dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT belkaclaus dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate
AT corradinistefanie dosimetricbenefitofmrguidedonlineadaptiveradiotherapyindifferenttumorentitiesliverlungabdominallymphnodespancreasandprostate